Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease.
Adolescent
Adult
Child
Child, Preschool
Disease Progression
Distal Myopathies
/ diagnosis
Female
Humans
Infant
Infant, Newborn
Magnetic Resonance Imaging
Male
Middle Aged
Muscle Weakness
/ physiopathology
Muscular Atrophy
/ diagnosis
Muscular Dystrophies, Limb-Girdle
/ diagnosis
Phenotype
Young Adult
[16] Clinical neurology examination
[176] All neuromuscular disease
[185] Muscle disease
[21] Clinical trials methodology
[54] Cohort study
Journal
Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
12
11
2020
revised:
13
01
2021
accepted:
18
01
2021
pubmed:
22
2
2021
medline:
19
11
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments.
Identifiants
pubmed: 33610434
pii: S0960-8966(21)00010-9
doi: 10.1016/j.nmd.2021.01.009
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-280Subventions
Organisme : Medical Research Council
ID : MR/S005021/1
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.